ライフサイエンスコーパス: antifungal

1 om survival without therapy to death despite antifungals.

2 conazole when used in combination with those antifungals.

3 ch display reduced susceptibility to current antifungals.

4 tance of C. albicans to cell wall-perturbing antifungals.

5 ivities of ergosterol biosynthesis-targeting antifungals.

6 ons to support decisions for safely stopping antifungals.

7 t host toxicities that preclude their use as antifungals.

8 riteria that predict when it is safe to stop antifungals.

9 These results highlight the potent antifungal abilities of thyme EO in controlling A. flavu

10 new aromatic acylhydrazones, evaluated their antifungal activities (MIC(80) and time-kill profile) ag

11 d Tat-B showed low micromolar anticancer and antifungal activities and synergistic action in combinat

12 The highest antibacterial and antifungal activities were attributed to samples C1 and

13 nted in vitro antioxidant, antibacterial and antifungal activities, whereas no toxic effects were det

14 The alpha-TCsNe exhibited enhanced antifungal activity against aflatoxin secreting strain o

15 They have shown in vitro antifungal activity against Colletotrichum acutatum and

16 re, the present work aimed to: (i) determine antifungal activity against Colletotrichum gloeosporioid

17 synthetic phenylthiazole small molecules for antifungal activity against drug-resistant C. albicans.

18 r, two compounds demonstrated broad spectrum antifungal activity against six other clinically relevan

19 Baicalein showed potent antifungal activity against the four fungi tested.

20 pressive activity and retains broad-spectrum antifungal activity and efficacy in a murine model of in

21 modified (MsrA2) and evaluated in vitro for antifungal activity and phytotoxicity.

22 results thus identify Snf2 as a regulator of antifungal activity and pulcherriminic acid biosynthesis

23 The extracts had similar antifungal activity but did not reveal anti-inflammatory

24 d Abeta peptides enhance both phagocytic and antifungal activity from BV-2 cells.

25 han 1% of RTD-1 levels required for in vitro antifungal activity in 50% mouse serum, while inducing a

26 Jawsamycin displays antifungal activity in vitro against several pathogenic

27 he first report of cyclic depsipeptides with antifungal activity isolated from frog cutaneous bacteri

28 The antifungal activity of a library of twenty-four aromatic

29 Our work illustrates the antifungal activity of a structurally unique NCR peptide

30 The antifungal activity of all products was tested.

31 et out to highlight the in vitro and in vivo antifungal activity of an Ethanolic Extract of Red Brazi

32 IRGB10 targets the fungal cell wall, and the antifungal activity of IRGB10 causes hyphae damage, modi

33 novel antifungal adjuvant that augments the antifungal activity of itraconazole against a broad rang

34 This study enhances our understanding of the antifungal activity of Kampo medicine, and may contribut

35 derlying this association, which maps to the antifungal activity of liver-resident Kupffer cells.

36 Furthermore, this antifungal activity triggered significant apoptosis, via

37 Antifungal activity was assessed by the microbroth dilut

38 he absence of 12/15-LOX, although neutrophil antifungal activity was intact.

39 Three flavones (7, 8, 12) showed marked antifungal activity with MIC < 2.0 uM.

40 able impact on long term physical stability, antifungal activity, and inhibition of mycotoxin product

41 dge regarding their structural architecture, antifungal activity, and modes of action against plant f

42 ong the 29 bacterial isolates that exhibited antifungal activity, Pseudomonas cichorii showed the gre

43 A, was employed; this mutant has less potent antifungal activity, when compared to Hst-5.

44 tic sordarin derivatives with broad spectrum antifungal activity.

45 i root, has been shown to exhibit pronounced antifungal activity.

46 the compounds most likely involved in their antifungal activity.

47 erpene scaffold, a modification critical for antifungal activity.

48 This study identifies ospemifene as a novel antifungal adjuvant that augments the antifungal activit

49 viously reported that itraconazole, a common antifungal agent, can clinically improve or cure infanti

50 The Food and Drug Administration-approved antifungal agent, itraconazole (ITZ), has been increasin

51 sterols in eukaryotes, the major targets for antifungal agents and prospective targets for treatment

52 ons (MFCs), with higher MFCs of the triazole antifungal agents being seen for the South African linea

53 nd 1, warrant further investigation as novel antifungal agents for drug-resistant Candida infections.

54 il nanoemulsions can act as highly efficient antifungal agents in vitro.

55 Routine use of antifungal agents is not recommended.

56 Moreover, HHK3 is a molecular target for antifungal agents such as fludioxonil, which thereby int

57 The future development of new antifungal agents will rest with those who employ synthe

58 Supplementation of antifungal agents with interferon-gamma treatment slowed

59 ence of resistance to our limited arsenal of antifungal agents, necessitating the development of nove

60 caffeine resistance show cross-resistance to antifungal agents, suggesting that related heterochromat

61 AMS guidelines likely apply to stewarding of antifungal agents, there are additional considerations u

62 nsuming, delaying treatment with appropriate antifungal agents.

63 s as inhibitors of the OAT1 and OAT3, and as antifungal agents.

64 ceptibility profiles to clinically available antifungal agents.

65 between PD-1 inhibitors and immunomodulatory antifungal agents.

66 In addition, the antifungal amphotericin B reversed Serinc restriction, p

67 ere carried out to provide insights into the antifungal and anti-aflatoxigenic effects of thyme essen

68 The Ne-TML was assessed for its antifungal and anti-aflatoxin B(1) potential in vitro an

69 hey combat pathogens due to their antiviral, antifungal and antibacterial properties, and are conside

70 n, a tetracyclic polyketide with antibiotic, antifungal and anticancer properties, in S. cerevisiae.

71 ajor diterpenoid metabolite ferruginol, with antifungal and antitermite activity.

72 sive intestinal mucormycosis with aggressive antifungal and supportive care without surgical interven

73 ortant clinical applications as antibiotics, antifungals and anti-cancer agents.

74 Here, we describe our current arsenal of antifungals and elaborate on the resistance mechanisms C

75 reby affecting its survival upon exposure to antifungals and host immune response.

76 e fungal cell wall is the primary target for antifungals and is recognized by host immune cells.

77 ystems can provide discovery pathways to new antifungals and structurally intriguing metabolites.

78 The limited number of antifungals and the rising frequency of azole-resistant

79 s for the delivery of various antibacterial, antifungal, and antiviral therapeutics.

80 ery, cell targeting and imaging, anticancer, antifungal, and bactericidal actions, and biofilm format

81 peptides are reported to have antibacterial, antifungal, and other bioactivities.

82 r chemopreventive, antiviral, antibacterial, antifungal, antiparasitic, and neuroprotective effects.

83 he use of known clinical Hsp90 inhibitors in antifungal applications due to concomitant host toxicity

84 Azole antifungals are vital therapeutic options for treating i

85 o researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epid

86 rther threatens the limited armamentarium of antifungals available to treat these serious infections.

87 Antifungal bioplastic films were developed based on poly

88 age by exposure to triazole and echinocandin antifungals but not by exposure to amphotericin B or flu

89 A wide variety of antifungal chemical agents are available; however, the s

90 esistance to the most commonly used class of antifungal chemicals, the azoles.

91 es resistant to the triazoles, the frontline antifungal class used in medicine and agriculture to con

92 The present study aimed to identify antifungal components of Ou-gon and to determine their m

93 Active antifungal components were identified by liquid chromato

94 in response to gallic acid, a plant-produced antifungal compound.

95 Four chromatographic methods, targeting 56 antifungal compounds as well as volatiles, were combined

96 ally-friendly production, the use of natural antifungal compounds extracted by emerging technologies

97 Overall, 53 antifungal compounds were detected, of which 33 were in

98 o food security and compels discovery of new antifungal compounds.

99 oxicity activities, and can potentiate azole antifungal compounds.

100 , -$905.85 to -$378.84; p < 0.001) and total antifungal costs were unchanged from $1771.86 to $2027.5

101 , potential increases in graft failures, and antifungal costs.

102 rgosterol biosynthesis and susceptibility to antifungals could set the stage for the development of n

103 an intriguing target for development of new antifungal crop treatments.

104 s in at least one product inoculated with an antifungal culture compared to the controls.

105 owing consumer demand for clean label foods, antifungal cultures offer alternatives to chemical prese

106 Its pivotal role in antifungal defense and its central position in the patho

107 orylate Card9, an essential player in innate antifungal defense, to dampen downstream NF-kappaB and J

108 pe lectin receptors (CLRs) play key roles in antifungal defense.

109 e a robust scientific response to complement antifungal development and the implementation of infecti

110 molecular targets that can be exploited for antifungal development remains limited.

111 The overall antifungal DOT/1,000 patient days was improved after imp

112 atients with discordant results, and overall antifungal DOT/1,000 patient days.

113 Subsequent removal of the antifungal drug can lead to a dramatic loss of the CNV a

114 ng Cu-only SODs a possible target for future antifungal drug design.

115 An equally important aspect of modern antifungal drug development takes a balanced look at the

116 al drugs make turbinmicin a highly promising antifungal drug lead to help address devastating global

117 and necrosis, and for this, administering an antifungal drug may be of benefit.

118 novel mechanism for the rapid acquisition of antifungal drug resistance and provide genomic evidence

119 ding of the mechanistic principles governing antifungal drug resistance is fundamental for the develo

120 Treatment options are limited, and antifungal drug resistance is increasing.

121 es of filamentous fungal biofilms that drive antifungal drug resistance remain largely unknown.

122 g proteins that regulate fungal virulence or antifungal drug resistance, such as regulators of fungal

123 the base of A. fumigatus biofilms increases antifungal drug resistance.

124 s fungal biofilm physiology and contemporary antifungal drug resistance.

125 ey enzyme in this pathway, is an exploitable antifungal drug target.

126 d mice and mice treated with caspofungin, an antifungal drug that inhibits beta-1,3-glucan synthase.

127 Griseofulvin is an antifungal drug that inhibits FECH as an off-target effe

128 f clinical resistance may be attributable to antifungal drug tolerance.

129 Ciclopirox (CPX), an FDA-approved antifungal drug, has exhibited promising antitumor activ

130 ria, and flucytosine (5-FC), an FDA-approved antifungal drug.

131 rystal structures of P450 BM3 bound to azole antifungal drugs - with the BM3 DM heme domain bound to

132 ungal pathogens makes the development of new antifungal drugs a medical imperative that in recent yea

133 Over the last 3 decades, advances in antifungal drugs and early diagnosis have improved IFD o

134 osome missegregation to acquire tolerance to antifungal drugs and for nonmeiotic ploidy reduction aft

135 New antifungal drugs are urgently needed to address the emer

136 The limited number of antifungal drugs combined with the isolation of Candida

137 Antifungal drugs have their own toxicities and interact

138 We investigated the mechanism of action of antifungal drugs in the human pathogen Acanthamoeba cast

139 14alpha-demethylase (CYP51) is a target for antifungal drugs known as conazoles.

140 fety, and mode of action distinct from other antifungal drugs make turbinmicin a highly promising ant

141 Current antifungal drugs only demonstrate partial success in imp

142 f mutagenesis and resistance to 5FOA and the antifungal drugs rapamycin/FK506 (rap/FK506) and 5-fluor

143 Certain nutrients, stresses and antifungal drugs trigger beta-glucan masking, whereas ot

144 and the rate of acquisition of tolerance to antifungal drugs via aneuploidy.

145 vitro and in vivo, and to act together with antifungal drugs, suggesting Adh proteins could be inter

146 copy number CNVs during adaptation to azole antifungal drugs.

147 esistance to environmental stress, including antifungal drugs.

148 BM3 enzyme binds inefficiently to many azole antifungal drugs.

149 be due at least in part to excessive use of antifungal drugs.

150 the primary target of the most commonly used antifungal drugs.

151 hesis enzymes represent potential targets of antifungal drugs.

152 ibility to all three classes of contemporary antifungal drugs.

153 approach to enhance the activity of current antifungal drugs.

154 The antifungal echinocandin lipopeptide, acrophiarin, was ci

155 ne fungus Dendryphiella salina indicating an antifungal ecological role in its natural environment.

156 The antifungal effect of propolis extract, potassium sorbate

157 ecently identified fungicide that exerts its antifungal effect on susceptible Fusarium species by inh

158 ing known triazoles demonstrated synergistic antifungal effects against Aspergillus fumigatus (AF) in

159 llent broad-spectrum activity display potent antifungal effects against strains of Candida auris, an

160 rophilia, we suggest that RTD-1 mediates its antifungal effects in vivo by host directed mechanisms r

161 ing trans-cinnamaldehyde (2-10%) showed high antifungal efficacy against Penicillium sp. and Aspergil

162 The improved safety profile and antifungal efficacy of liposomal amphotericin B (LAmB) c

163 athogen defensive functions, whereas the low antifungal efficacy of tested sesquiterpenoids supports

164 The antifungal efficacy of these nanoemulsions and their sen

165 he resistance of the latter to a widely used antifungal fluconazole.

166 The azole class antifungal, fluconazole, is widely available and has mul

167 rugs, including the most commonly prescribed antifungal, fluconazole.

168 Identifying new antifungals for cryptococcal meningitis is a priority gi

169 portant FHB resistance gene with a potential antifungal function and probably a key functional compon

170 The primary screen revealed 44 non-antifungal hits were able to act synergistically with fl

171 study, we explored the role of platelets in antifungal host defense against C. albicans PBMCs were s

172 most cost-effective approach of the studied antifungals; however, the CEA was sensitive to potential

173 e RLR family to include a role in regulating antifungal immunity against A. fumigatus.

174 IL-1beta served an essential function in CNS antifungal immunity by driving production of the chemoki

175 kinase 3 (Dok3) adaptor negatively regulates antifungal immunity in neutrophils.

176 twork of host-pathogen interactions promotes antifungal immunity in the CNS; this is impaired in huma

177 Initiation of antifungal immunity involves fungal recognition by patte

178 el effort to address fungal pathogenesis and antifungal immunity, the mycobiota and colonization resi

179 n innate immune crosstalk underlying mucosal antifungal immunity.

180 t is involved in C-type lectin signaling and antifungal immunity.

181 Mincle receptor, providing new insights into antifungal immunity.

182 l. (2020) reveal a critical role for pDCs in antifungal immunity.

183 ource of infection, days of therapy (DOT) of antifungals in patients with discordant results, and ove

184 accharomyces cerevisiae for the discovery of antifungal inhibitors of GPI-anchoring of proteins, and

185 ve blood cultures that may allow for earlier antifungal interventions and includes C. auris, a highly

186 prove the knowledge about the action mode of antifungal lactobacilli.

187 umigatus challenge through the regulation of antifungal leukocyte responses in mice.

188 s, prompt ART initiation, and more intensive antifungals may reduce mortality among asymptomatic CrAg

189 nd 10% of suspected patients were prescribed antifungal medication in the outpatient setting.

190 Most cases require treatment with systemic antifungal medication, but it might not be necessary to

191 Seven of the 9 patients received systemic antifungal medication, including both disseminated cases

192 anticancer drugs, antibiotics, antiviral and antifungal medicines, drugs affecting the urinary system

193 metabolomics to identify previously unknown antifungal metabolites in maize seedling roots, and inve

194 the presence of cutaneous bacteria producing antifungal metabolites.

195 ss of the current reserve of antibiotics and antifungals, methodological advances open additional ave

196 The CS-PAEO-Nm exhibited improved antifungal (minimum inhibitory concentration = 0.08 muL/

197 The speculated antifungal mode of action of Ne-TML was related to the d

198 enomic tools, we identified encouraging lead antifungal molecules with in vivo efficacy.

199 d C. auris, exhibiting resistance to current antifungals necessitates the development of new therapeu

200 se was critical for the induction of optimal antifungal neutrophil killing of A. fumigatus spores.

201 herichia coli, but no further antibacterial, antifungal nor cytotoxic effects.

202 iasis, suggesting the existence of essential antifungal pathways mediated by IL-17F and/or IL-17AF.

203 of the small, rationally designed synthetic antifungal peptide PAF26 using the model fungus Neurospo

204 Antifungal peptides represent a useful source of antifun

205 dopsis thaliana) efficiently synthesizes the antifungal phytoalexin camalexin without the apparent re

206 f SAARs for narrow-spectrum B-lactam agents, antifungals predominantly used for invasive candidiasis,

207 potential and can be recommended as a novel antifungal preservative to improve the shelf-life of sto

208 tracted phytochemicals were found but in the antifungal properties (MAE against P. italicum and HHP a

209 n vitro results showed that EERBP had strong antifungal properties againstC.

210 Essential oils are known to possess natural antifungal properties, becoming a reliable alternative f

211 d a clinical practice guideline for systemic antifungal prophylaxis administration in pediatric patie

212 pse post-HSCT and careful drug selection for antifungal prophylaxis are of paramount importance.

213 Standard antifungal prophylaxis consisted of aerosolized amphoter

214 We conducted a systematic review of systemic antifungal prophylaxis in children and adults with cance

215 ocandin or a mold-active azole when systemic antifungal prophylaxis is warranted.

216 ng using a strategic diagnostic approach and antifungal prophylaxis of patients with risk factors wil

217 on may be used for decision making regarding antifungal prophylaxis or closely monitoring patients at

218 e data suggest benefit in providing systemic antifungal prophylaxis targeting Candida for up to 90 da

219 mmendations were made to administer systemic antifungal prophylaxis to children and adolescents recei

220 e administration of amphotericin as systemic antifungal prophylaxis was made.

221 121 (72%) occurred in the absence of recent antifungal prophylaxis; however, IC and non-Candida brea

222 We reasoned that clinically relevant antifungal resistance could derive from transcriptional

223 Triazole antifungal resistance in A. fumigatus has become recogni

224 The antifungal resistance of plants with high MsrA2 expressi

225 Furthermore, despite exhibiting enhanced antifungal resistance, high iron C. albicans cells had r

226 therapeutic strategies that may help combat antifungal resistance, including combination therapy, ta

227 The frequency of antifungal resistance, particularly to the azole class o

228 nmental reservoirs to mitigate the spread of antifungal resistance.

229 ts high mortality rate, due primarily to its antifungal resistance.

230 High-systemic toxicity and emergence of antifungal-resistant species warrant the development of

231 ether, this study proposes a model of how an antifungal response translates to the expression of proi

232 reduction in type 1 (antiviral) and type 3 (antifungal) responses.

233 l resistance to fluconazole by reversing the antifungal's effect on the ergosterol biosynthesis pathw

234 to the species level is required for proper antifungal selection.

235 Although much is known about the antifungal spectrum of phenamacril, the exact mechanism

236 ratory Standards Institute antimicrobial and antifungal standards define a susceptible-dose-dependent

237 However, the subject of antifungal stewardship (AFS) has received less attention

238 standardized and is a challenging subject in antifungal stewardship.

239 acilitate informed therapy decisions and aid antifungal stewardship.

240 Whereas conventional antifungal strategies target proteins or cellular compon

241 easibility of targeting Hsp90 as a promising antifungal strategy.

242 For grafts intended for PKs, antifungal supplementation was less cost-effective than

243 For full-thickness corneal grafts, antifungal supplementation was less cost-effective.

244 Antifungal supplementation with amphotericin B for EK gr

245 compared the phenotypic characteristics and antifungal susceptibilities of isolates representative o

246 We found no correlation between antifungal susceptibility and either early or late survi

247 ich can be useful for studying epidemiology, antifungal susceptibility patterns, and diagnostic metho

248 performed whole-genome sequencing (WGS) and antifungal susceptibility testing (AFST) on all isolates

249 and other yeasts from surveillance samples, antifungal susceptibility testing to determine the C. au

250 Antifungal susceptibility testing was in agreement with

251 Antifungal susceptibility testing was performed as outli

252 ive infection, combining identification with antifungal susceptibility, and navigating the administra

253 f which play critical roles in virulence and antifungal susceptibility.

254 present an overview of current knowledge of antifungal T cell immune responses, with emphasis on the

255 ure exploration of Cdc14 as a broad spectrum antifungal target for plant protection.

256 tural, and chemical evidence that Gna1 is an antifungal target in A. fumigatus.

257 portant for fungal virulence and a potential antifungal target, but compounds targeting calcineurin,

258 ammalian taxa, Tpt1 is seen as an attractive antifungal target.

259 in fungi and have been proposed as potential antifungal targets.

260 tors will accelerate the design of selective antifungals that can be deployed to combat life-threaten

261 ontribute to the development of new and safe antifungal therapeutics.

262 fections may fail to respond to contemporary antifungal therapies in vivo despite in vitro fungal iso

263 Despite aggressive antifungal therapies, outcomes of CNS cryptococcosis in

264 da spp., highlighting the urgent need of new antifungal therapies.

265 tically significant differences in empirical antifungal therapy (71.9% caspofungin vs 69.5% fluconazo

266 The mortality rate was reduced by the use of antifungal therapy (Mortality: 38.5% in patients receivi

267 (P = .016), despite switching to appropriate antifungal therapy after a median of 10 days.

268 cohort of patients not treated with standard antifungal therapy allowing for characterization of the

269 ients with low CrAg titers were treated with antifungal therapy and 22 (81%) responded well clinicall

270 sociated with poor clinical response despite antifungal therapy and negative CSF cultures.

271 vival benefit observed in patients receiving antifungal therapy implies that the proposed diagnostic

272 re fulminant meningitis develops, when early antifungal therapy improves survival.

273 has been arrested, and in those situations, antifungal therapy is unlikely to yield clinical improve

274 To avoid treatment delay, antifungal therapy might be systematically discussed in

275 issue stored in CSM or CSM supplemented with antifungal therapy over a 16-year time horizon.

276 clear how a targeted prophylaxis/ preemptive antifungal therapy strategy impacts the incidence of IPA

277 A delay in the initiation of appropriate antifungal therapy was associated with increased overall

278 n the consultation group, median duration of antifungal therapy was longer (18 [IQR 14-35] vs 14 [6-2

279 comes were invasive aspergillosis, empirical antifungal therapy, and overall survival.

280 alized assessment for the continued need for antifungal therapy.

281 hile accounting for the influences of IC and antifungal therapy.

282 olates from a randomized controlled trial of antifungal treatment (amphotericin monotherapy, amphoter

283 Delayed implementation of effective antifungal treatment caused by inefficient Candida diagn

284 The median time from antifungal treatment to steroid initiation was 6 weeks.

285 t-, malignancy-, transplantation procedure-, antifungal treatment-, and fungus-specific issues affect

286 film maturation but also drive resistance to antifungal treatment.

287 nts often results in prolonged or indefinite antifungal treatment.

288 ruit leaf extracts as a suitable postharvest antifungal treatment.

289 VC) is common among women, but current azole antifungal treatments are often associated with safety a

290 mortality, triazole-resistance profiles, and antifungal treatments were investigated.

291 Despite the availability of antifungal treatments, mortality rates are still unaccep

292 hen to continue, discontinue, or reinstitute antifungal treatments.

293 d patients and treatment outcomes using oral antifungal triazoles remain suboptimal.

294 Oats produce avenacins, antifungal triterpenes that are synthesized in the roots

295 , predisposing factors, all-cause mortality, antifungal use, central-line removal, and ophthalmologic

296 sured anti-infective (antibiotic, antiviral, antifungal) use hospital-wide by unit and by drug for an

297 One of its key antifungal virulence factors is the type IV pili that ar

298 Resistance to multiple antifungals was frequent, and three isolates were recove

299 Voriconazole, caspofungin, and combination antifungals were less cost-effective than amphotericin B

300 fungal peptides represent a useful source of antifungals with novel mechanisms-of-action, and potenti